Skip to main content

Table 3 Multiple logistic regression for factors associated with grade 4 Lymphopenia

From: Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort

Variable

 

Grade 4 Lymphopenia

OR(95%CI)

SE

AIC

p

Thoracic TVB

    

 Thoracic vertebrae V20

1.02(0.99–1.04)

0.011

-

0.18

 Thoracic vertebrae V10

1.03(1.01–1.06)

0.012

188.8

0.005

 Thoracic vertebrae V5

1.03(1.02–1.06)

0.012

185.5

0.0012

 Mean thoracic vertebrae dose

1.11(1.03–1.20)

0.038

189.4

0.0069

Mean cardiopulmonary dose

1.32(1.12–1.56)

0.084

185.0

0.00083

Mean whole body dose

1.41(1.04–1.92)

0.16

192.8

0.028

Ribs

    

 V5

1.03(0.99–1.04)

0.012

-

0.15

 Mean ribs dose

1.33(1.09–1.63)

0.1

189.9

0.0055

Spleen dose

    

 V30

1.02(0.99–1.04)

0.012

-

0.12

 V20

1.02(1.00-1.03)

0.008

192.6

0.017

 V10

1.02(1.01–1.03)

0.006

188.9

0.003

 V5

1.02(1.01–1.03)

0.006

184.7

0.0045

Mean spleen dose

1.11(1.05–1.18)

0.03

185.6

0.00042

  1. Abbreviations: SE: standard error; OR: odds ratio; TVB, Thoracic Vertebral Body;
  2. *Models included one dosimetric parameter and each of the following covariates: age (continuous), BMI (continuous), nCRT regimen, Sex and tumor length (continuous)